Healthcare, Pharma & Life Sciences

Dentsply Sirona and AADOCR Name 2026 SCADA Award Winners Across Clinical and Translational Dental Research

Image
Dentsply Sirona and AADOCR Name 2026 SCADA Award Winners Across Clinical and Translational Dental Research

SHERIDAN, WYOMING - May 13, 2026 - Dentsply Sirona and the American Association for Dental, Oral, and Craniofacial Research (AADOCR) have announced the winners of the 2026 Student Competition for Advancing Dental Research and its Application (SCADA) Awards, recognizing pre-doctoral dental students for research excellence across clinical and basic science disciplines. The awards were presented during the 55th Annual Meeting of AADOCR, held in conjunction with the 104th General Session and Exhibition of the IADR and the 50th Annual Meeting of the Canadian Association for Dental Research, at the San Diego Convention Center from March 25 to 28, 2026. This year's competition drew 61 dental students from across the United States and seven international finalists from Canada, France, Thailand, Taiwan, South Korea, and Japan.

Roche Wins CE Mark for Elecsys pTau217 Blood Test to Detect Alzheimer's Amyloid Pathology in Routine Care

Image
Roche Wins CE Mark for Elecsys pTau217 Blood Test to Detect Alzheimer's Amyloid Pathology in Routine Care

SHERIDAN, WYOMING - May 13, 2026 - Roche has received CE Mark for Elecsys® pTau217, a blood-based diagnostic test designed to detect amyloid pathology associated with Alzheimer's disease, developed in collaboration with Eli Lilly and Company. The test measures phosphorylated Tau 217 protein from a routine blood draw and is intended to rule in or rule out amyloid pathology across both primary and secondary care settings using a single-assay design with unified cutoffs. The regulatory clearance positions Elecsys® pTau217 for deployment across Roche's installed base of laboratory instruments in CE mark-accepting countries, with potential FDA clearance in the United States under consideration for later this year.

TuHURA Biosciences CEO to Present Phase 3 Oncology Pipeline at H.C. Wainwright BioConnect Conference

Image
TuHURA Biosciences to Highlight Phase 3 Immuno-Oncology Pipeline at H.C. Wainwright BioConnect Conference

SHERIDAN, WYOMING - May 13, 2026 - TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy, has confirmed that President and Chief Executive Officer James A. Bianco, M.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City on May 19, 2026, at 2:00 pm ET. The appearance gives institutional investors and sector analysts direct access to leadership at a moment when TuHURA is running an active Phase 3 registration trial and advancing two additional pipeline programs. For stakeholders tracking immuno-oncology development timelines and clinical positioning, the session represents a structured opportunity to assess the company's near-term milestones.

Fette Compacting Introduces R&D Solutions to Accelerate Pharmaceutical Tableting and Scale-Up Processes

Image
Fette Compacting Introduces R&D Solutions to Accelerate Pharmaceutical Tableting and Scale-Up Processes

SHERIDAN, WYOMING - May 10, 2026 - Fette Compacting has formally introduced its comprehensive R&D Solutions program, transitioning the company from a traditional equipment supplier to an integrated process partner for pharmaceutical manufacturers. The newly structured service framework supports drug developers from initial powder formulation through to validated commercial serial production. By embedding Quality by Design principles early in the development lifecycle, the initiative directly addresses the critical need to accelerate time-to-market and maximize effective patent exclusivity periods. This strategic realignment aims to eliminate isolated development steps, ensuring that complex critical material attributes are seamlessly aligned with final production parameters.

SBC Medical Posts Q4 EPS Doubling While Launching Performance Medicine Push Into $2 Trillion Longevity Market

Image

SHERIDAN, WYOMING - April 14, 2026 - SBC Medical Group Holdings Incorporated (Nasdaq: SBC), an Irvine, California-based Management Services Organization, reported fourth-quarter earnings per share more than doubling to $0.14, marking a significant year-over-year improvement in profitability. The results, disclosed on March 27, arrived alongside the company's announcement of a full-scale entry into the longevity healthcare market through a newly defined "Performance Medicine" category. SBC Medical simultaneously disclosed the acceleration of its multi-branding strategy in aesthetic healthcare, including expansion into Tokyo's premier district. Together, the three announcements signal both financial recovery and a deliberate pivot toward higher-growth healthcare verticals.

Corvex and Movano Complete All-Stock Merger as Corporate and Compliance Pressures Converge

Image

SHERIDAN, WYOMING - April 14, 2026 - Corvex and Movano Health have announced the closing of their all-stock merger, completing a structural consolidation for the Pleasanton, California-based developer of women's health wearables. The transaction follows a sequence of concurrent corporate developments at Movano, including a Nasdaq deficiency notification tied to a delayed quarterly filing and a board-initiated process to evaluate options for maximizing shareholder value. Movano's portfolio centers on the Evie Ring, a smart ring designed specifically for women's health monitoring, and a patented radio frequency platform targeting non-invasive blood pressure and glucose measurement. Together, these developments mark a period of significant transition for the company across its corporate, regulatory, and product dimensions.

Nanodropper's FDA-Listed Adaptor Targets 80% Eyedrop Waste With Volume-Reducing Design

Image

SHERIDAN, WYOMING - April 14, 2026 - Nanodropper has developed the only FDA-listed, volume-reducing adaptor for commercial eyedrop bottles, targeting a structural inefficiency in ophthalmic drug delivery that decades of clinical research have identified but pharmaceutical packaging has not resolved. The device attaches by twisting onto a compatible bottle and reduces dispensed drop volume by more than 60%. Standard eyedrop bottles produce drops approximately five times larger than the eye can absorb, causing up to 80% of each dose to be lost through facial overflow or tear duct drainage into systemic circulation. Clinical evidence indicates smaller drops deliver equivalent therapeutic effect while reducing systemic absorption and associated side effects.

DarioHealth Reports 3.4-6x Partner ROI Across Integrated Chronic Condition Platform

Image

SHERIDAN, WYOMING - April 14, 2026 - DarioHealth Corp. (Nasdaq: DRIO), a digital health company focused on chronic condition management, operates an integrated platform spanning metabolic health, musculoskeletal care, and behavioral health under a unified coaching architecture designed for employer and health plan markets. The company reports that members average 2.4 chronic conditions on the platform, with 80% retention and a stated 3.4-6x return on investment for organizational partners. DarioHealth distributes through employers, benefits consultants, health plans, and pharmaceutical companies, positioning its single-platform model as a consolidation tool for enterprise buyers seeking to reduce fragmentation in chronic care benefits. Clinical outcomes data - including a 1.4% reduction in eA1c and $2,322 in average per-employee savings - underpin a financial accountability model increasingly demanded by self-insured employers.

PTC Therapeutics Names Morgan Stanley Biotech Banking Pioneer Jessica Chutter to Board of Directors

Image

SHERIDAN, WYOMING - April 14, 2026 - PTC Therapeutics has appointed Jessica Chutter to its Board of Directors, adding a seasoned biotechnology investment banker who built and led Morgan Stanley's biotechnology franchise over an extensive tenure at the firm. The appointment brings capital markets expertise directly into PTC's governance structure at a time when the company operates multiple approved therapies across the U.S. and international markets and continues to invest in a diversified rare disease pipeline. Chutter is described by the company as a highly accomplished biotechnology investment banker with an extensive list of achievements. The board addition reinforces PTC's strategic focus on commercialization and financial positioning in specialty pharma.

BBB National Programs Launches Creator Certification, AI-Kids Risk Matrix, and Political Ad Guidance in 2026 Program Push

Image

SHERIDAN, WYOMING - April 14, 2026 - BBB National Programs has accelerated its 2026 program agenda across advertising accountability, children's digital privacy, and influencer marketing, introducing a creator certification initiative and publishing a generative AI risk matrix for products targeting children. The organization operates more than 20 self-regulation and dispute resolution programs in the United States, tracing its founding of the National Advertising Division to 1971. Its current expansion addresses converging pressures around AI risk, cross-border data obligations, and federal children's privacy enforcement now landing simultaneously on compliance calendars.